♥️Top 10 Reasons To Love BIEL (2026 Edition)♥️
A Pre-IPO Style VC Opportunity Entering Full Commercial Scale
100%+ Revenue Growth Forecast Every Year
Momentum is Built-In With the Recent 400% PPS Surge!
1. Seed Stage Valuation for a Commercial Stage Company
BIEL trades at a $5M–$10M market cap, the valuation of a seed stage startup — despite having FDA cleared products, clinical validation, global distribution, and a commercial partner scaling into thousands of locations. This is the exact asymmetric setup VCs hunt for.
2. FDA Cleared, Clinically Proven Technology (Not Speculative Biotech)
ActiPatch® and RecoveryRx® have multiple FDA clearances, peer reviewed studies, and real world outcomes — including Stanford supported arthritis data. Electrome’s PAINKILLER™ platform requires BIEL hardware in every kit, guaranteeing OEM demand.
3. A Defensible Moat With Patents + Regulatory Barriers
BIEL owns utility patents, regulatory clearances, and 30 years of clinical data (Phantom pain, Stanford Thumb Study, etc.)— assets that would cost tens of millions to replicate. This is a true electroceutical moat.
4. Institutional Adoption Already in Motion
BIEL’s hardware is entering:
• The U.S. VA system (largest healthcare network in America)
• International markets across Europe and Asia
• The veterinary health sector
• And now: 3,700 national pharmacy locations in late 2026
This is the classic institutional adoption curve: clinical - government - retail - global.
5. The 3,700 Store Retail Rollout (Late 2026)
Electrome cannot ship a single PAINKILLER™ unit without BIEL’s OEM module. The rollout triggers:
Pipeline Fill (Late 2026)
• 5–10 units per store
• 18,500–37,000 units
• $277,500–$555,000 immediate revenue
Restock Velocity (2027)
• 2–4 units per store per month
• 88,800–177,600 units annually
• $1.33M–$2.66M recurring revenue
This is the first true commercial scale inflection point in company history.
6. Razor Blade Revenue Model (100%+ Growth Every Year) With Zero Scaling Costs
Electrome pays for:
• Marketing
• Distribution
• Retail slotting fees
• Consumer acquisition
BIEL pays for none of it. BIEL simply collects OEM revenue on every module shipped. This is a VC grade margin profile.
7. A Commercial Timeline Already Lined Up Through 2027
• Q1–Q2 2026: VA deployments = active revenue
• Q2–Q3 2026: Early commercial rollout ($0.75M–$2.25M modeled)
• Q3–Q4 2026: 3,700 store onboarding
• 2027: Full retail restock velocity + veterinary + global expansion
This is the exact S curve venture capitalists look for.
8. Extreme Profitability Potential (Ultra Lean Model)
BIEL historically converts revenue into profit at unusually high rates:
• Q3 2021: $22,381 profit on $414,700 revenue
• Estimated today: $3M revenue = $2.5M net profit
• Supported by a $40M tax loss carryforward
This is why early hypergrowth companies trade at P/E ratios of 500–1,000.
9. A Clear PPS Ladder With Real Revenue Behind It
Based on modeled revenue (more than doubling every year) and commercial catalysts:
• $0.001 — Technical breakout
• $0.01 — Cash flow positive ($1M+ 2026)
• $0.10 — Retail scale ($3M+ revenue, 2027)
• $1.00 — Post debt, buyback era (2028)
This is the kind of exponential curve VCs chase — except here, retail investors can still enter at sub penny levels.
10. A True Pre IPO Style VC Opportunity — Without the Gatekeepers
BIEL offers retail investors what Wall Street normally keeps for itself:
• Seed stage valuation
• De risked, FDA cleared tech
• Institutional distribution
• A razor blade revenue engine
• A 3,700 store rollout already scheduled
• Near zero operating costs
• A path to profitability that mirrors early hypergrowth companies
This is the closest thing retail investors get to a real pre-IPO, venture capital ground floor. Momentum is built-in with the recent 400% PPS surge, and the commercial scale event is on the calendar.
A Pre-IPO Style VC Opportunity Entering Full Commercial Scale
100%+ Revenue Growth Forecast Every Year
Momentum is Built-In With the Recent 400% PPS Surge!
1. Seed Stage Valuation for a Commercial Stage Company
BIEL trades at a $5M–$10M market cap, the valuation of a seed stage startup — despite having FDA cleared products, clinical validation, global distribution, and a commercial partner scaling into thousands of locations. This is the exact asymmetric setup VCs hunt for.
2. FDA Cleared, Clinically Proven Technology (Not Speculative Biotech)
ActiPatch® and RecoveryRx® have multiple FDA clearances, peer reviewed studies, and real world outcomes — including Stanford supported arthritis data. Electrome’s PAINKILLER™ platform requires BIEL hardware in every kit, guaranteeing OEM demand.
3. A Defensible Moat With Patents + Regulatory Barriers
BIEL owns utility patents, regulatory clearances, and 30 years of clinical data (Phantom pain, Stanford Thumb Study, etc.)— assets that would cost tens of millions to replicate. This is a true electroceutical moat.
4. Institutional Adoption Already in Motion
BIEL’s hardware is entering:
• The U.S. VA system (largest healthcare network in America)
• International markets across Europe and Asia
• The veterinary health sector
• And now: 3,700 national pharmacy locations in late 2026
This is the classic institutional adoption curve: clinical - government - retail - global.
5. The 3,700 Store Retail Rollout (Late 2026)
Electrome cannot ship a single PAINKILLER™ unit without BIEL’s OEM module. The rollout triggers:
Pipeline Fill (Late 2026)
• 5–10 units per store
• 18,500–37,000 units
• $277,500–$555,000 immediate revenue
Restock Velocity (2027)
• 2–4 units per store per month
• 88,800–177,600 units annually
• $1.33M–$2.66M recurring revenue
This is the first true commercial scale inflection point in company history.
6. Razor Blade Revenue Model (100%+ Growth Every Year) With Zero Scaling Costs
Electrome pays for:
• Marketing
• Distribution
• Retail slotting fees
• Consumer acquisition
BIEL pays for none of it. BIEL simply collects OEM revenue on every module shipped. This is a VC grade margin profile.
7. A Commercial Timeline Already Lined Up Through 2027
• Q1–Q2 2026: VA deployments = active revenue
• Q2–Q3 2026: Early commercial rollout ($0.75M–$2.25M modeled)
• Q3–Q4 2026: 3,700 store onboarding
• 2027: Full retail restock velocity + veterinary + global expansion
This is the exact S curve venture capitalists look for.
8. Extreme Profitability Potential (Ultra Lean Model)
BIEL historically converts revenue into profit at unusually high rates:
• Q3 2021: $22,381 profit on $414,700 revenue
• Estimated today: $3M revenue = $2.5M net profit
• Supported by a $40M tax loss carryforward
This is why early hypergrowth companies trade at P/E ratios of 500–1,000.
9. A Clear PPS Ladder With Real Revenue Behind It
Based on modeled revenue (more than doubling every year) and commercial catalysts:
• $0.001 — Technical breakout
• $0.01 — Cash flow positive ($1M+ 2026)
• $0.10 — Retail scale ($3M+ revenue, 2027)
• $1.00 — Post debt, buyback era (2028)
This is the kind of exponential curve VCs chase — except here, retail investors can still enter at sub penny levels.
10. A True Pre IPO Style VC Opportunity — Without the Gatekeepers
BIEL offers retail investors what Wall Street normally keeps for itself:
• Seed stage valuation
• De risked, FDA cleared tech
• Institutional distribution
• A razor blade revenue engine
• A 3,700 store rollout already scheduled
• Near zero operating costs
• A path to profitability that mirrors early hypergrowth companies
This is the closest thing retail investors get to a real pre-IPO, venture capital ground floor. Momentum is built-in with the recent 400% PPS surge, and the commercial scale event is on the calendar.
